Dalrada Technology Group Inc.
Moat Score — Dalrada Technology Group Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Genefic Specialty Pharmacy holds pharmacy licenses across all 50 states and D.C., a real regulatory asset, and Prakat carries ISO 9001 certification, but the company has no meaningful patent portfolio and spent $0 on R&D in both FY2025 and FY2024, so these intangibles are narrow rather than broad-based. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | There is no evidence of a structural cost advantage; gross margin was only about 5% in FY2024 and the company posted net losses of $24.7 million (FY2025) and $29.2 million (FY2024), consistent with a sub-scale operator rather than a low-cost producer. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | FY2025 gross margin improved to roughly 26% from about 5% the prior year, suggesting some pricing improvement, but with a stockholders' deficit and going-concern doubt, Dalrada is in no position to command premium pricing broadly across its pharmacy, HVAC, manufacturing, and IT segments. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | None of Dalrada's five divisions (specialty pharmacy, climate technology, precision manufacturing, Prakat IT services, corporate) exhibit network effects; each customer relationship (a patient, a building owner, a contract-manufacturing client, an IT client) is independent of how many other customers the company has. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Genefic's infusion and specialty pharmacy patients have some continuity tied to insurance authorizations and prescriber relationships, and Prakat's enterprise software-testing engagements carry modest re-contracting friction, but neither creates a strong lock-in across the broader, declining Genefic and Precision Manufacturing segments. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Deposition Technologies' PVD/CVD equipment refurbishment and OEM-parts niche is narrow enough that large players like Applied Materials or Veeco have limited incentive to chase it, giving that sliver of the business some efficient-scale protection, but the company's other divisions operate in large, contested markets (specialty pharmacy, HVAC, offshore IT) with no scale protection at all. |